Subarachnoid Hemorrhage, Aneurysmal Clinical Trial
Official title:
Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage and Systemic Response to Endogenous Stress. Urinary and Serum Factors and Clinical Developments. Pilot Study Toward the Predictivity of Clinical Failure and Variation on Outcome in the Neurosurgical Patient (HISAHES)
The goal of this observational study is to learn about the role of biomarkers in spontaneous subarachnoid hemorrhage (sSAH) as predictors of severity of clinical outcome. The test of biomarkers is based on regular blood and urinary samples. Blood levels of highly specific cardiac troponin (cTNI), natriuretic peptides (NT-ProBNP), S100 beta protein, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase (UCH-L1), soluble Tumor Necrosis Factor Receptor-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR), as well as urinary levels of epinephrine and norepinephrine are the biomarkers explored. All adult participants with spontaneous subarachnoid hemorrhage are involved in the study. The main questions aim to answer are: - which of these molecules can be prognostic for patients' outcome - which are the prognostic levels of these biomarkers to predict patients' outcome. Participants will undergo blood and urinary samples during hospitalization at 24 hours, 72 hours and after 7 days.
Spontaneous subarachnoid hemorrhage (sSAH) is one of the most severe neurological conditions. The hemodynamic instability due to endogenous catecholamine response and inflammatory patterns influences the risk of an unfavorable outcome and the development of clinical implications such as neurological and non-neurological issues. Serum levels of highly specific cardiac troponin (cTNI), natriuretic peptides (NT-ProBNP), S100 beta protein, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase (UCH-L1), soluble Tumor Necrosis Factor Receptor-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR), as well as urinary levels of epinephrine and norepinephrine, can be measured as biomarkers in sSAH to explore the systemic response to the stress of bleeding. However, not all sSAH cases equally develop this endogenous cascade responsible for neurological and systemic events. There is no clear validation of threshold levels of endogenous factors applicable in clinical practice to define hemodynamic instability that has only a neurological or multi-organ impact post-SAH. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032533 -
Remote Ischemic Conditioning in Aneurysmal SAH
|
N/A | |
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Recruiting |
NCT06006975 -
Early Warning of Delayed Cerebral Ischemia
|
||
Terminated |
NCT02893826 -
Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH
|
Phase 1 | |
Unknown status |
NCT01567449 -
Risk Factors for Aneurysm Rebleeding
|
N/A | |
Recruiting |
NCT05095857 -
The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
|
Phase 4 | |
Not yet recruiting |
NCT04512859 -
Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT05103566 -
Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Not yet recruiting |
NCT04696523 -
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT04415736 -
Artificial Intelligence in Subarachnoid Hemorrhage
|
||
Recruiting |
NCT05925478 -
Pterygopalatine Fossa Block in Aneurysmal Subarachnoid Hemorrhage
|
Early Phase 1 | |
Recruiting |
NCT04649398 -
Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration
|
||
Recruiting |
NCT02995928 -
Trial of Prophylactic Decompressive Craniectomy for Poor-grade Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT04945603 -
Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group
|
||
Active, not recruiting |
NCT06239142 -
Understanding Mental Fatigue After Subarachnoid Hemorrhage
|
||
Completed |
NCT03318783 -
Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
|
Phase 1/Phase 2 | |
Terminated |
NCT05686265 -
Cerebral Nitrosative/Oxidative Stress in Aneurysmal Subarachnoid Haemorrhage
|
||
Not yet recruiting |
NCT06359782 -
Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)
|
Phase 2 | |
Not yet recruiting |
NCT06057155 -
Intracranial Pressure and Optic Nerve Sheath Diameter With CLOSED Bundle
|